Her-2阳性结直肠癌的诊治进展

Progress in diagnosis and treatment of Her-2 positive colorectal cancer

结直肠癌是最常见的消化道恶性肿瘤之一,近年来随着精准治疗理念的提出及精准诊断技术的改进,关于Her-2阳性的结直肠癌逐步引起学者的关注。Her-2阳性结直肠癌总体约占5%,包括Her-2过表达,ERBB2基因扩增及突变。目前对于标准治疗失败的Her-2过表达或扩增的结直肠癌患者已有诸多研究证实靶向Her-2治疗的可行性,但Her-2突变型患者目前尚无确切可行的治疗策略。笔者就近年来Her-2阳性结直肠癌的诊治进展作一概述。

Colorectal cancer is one of the most common malignant tumors of digestive tract. In recent years, with the introduction of the concept of precision treatment and the improvement of precision diagnosis technology, scholars have gradually paid attention to Her-2 positive colorectal cancer, which accounts for about 5%, including Her-2 overexpression, ERBB2 gene amplification and mutation. At present, many studies have confirmed the feasibility of targeting Her-2 in colorectal cancer patients with overexpression or amplification of Her-2 that fail to receive standard treatment, but there is no definite and feasible treatment strategy for Her-2 mutant patients. This article reviews the progress in the diagnosis and treatment of Her-2 positive colorectal cancer in recent years.